Anatumomab mafenatox
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | TAG-72 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (verify) | |
Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer, which acts as a tumor-targeted superantigen.
It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.
Development was abandoned in 2005.